Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1653 in Adults and Children
NCT04144348Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mRNA-1653 in human metapneumovirus infection (HMPV) and human parainfluenza virus type 3 infection (PIV3) (4 arms), sponsored by Moderna Inc. Primary endpoints: Proportion of Participants with Solicited Local and Systemic Adverse Reactions, Proportion of Participants with Unsolicited Adverse Events and 1 more. Started Nov 2019; status: completed.
02
Drugs
mRNA-1653
03
Conditions
human metapneumovirus infection (HMPV)human parainfluenza virus type 3 infection (PIV3)
Beyond the preview
Go deeper on NCT04144348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144348.